StreetInsider.com News Articles

NeuroThera Labs completes manufacturing milestone for Tourette trial

Thu, 22 Oct 2026 08:59:26 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) has completed manufacturing of its investigational drug candidate SCI-110 and obtained batch release certification from a European Qualified Person, clearing the way for shipment of clinical trial materials to study sites.

The certification is a regulatory step that authorizes the distribution of clinical supply for NeuroThera's FDA-approved Phase IIb clinical trial evaluating SCI-110 for the treatment of Tourette syndrome in adults. The company said all three participating clinical sites have completed initiation activities and are prepared to receive drug supplies, with shipments expected in the near term.

The trial

NeuroThera Labs completes manufacturing milestone for Tourette trial

Thu, 22 Oct 2026 08:59:26 -0400

The trial

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.

NeuroThera has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

Clearmind patent application for dyskinesia treatment published in Japan

Thu, 08 Oct 2026 07:34:26 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) announced the publication of a patent application in Japan covering compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements.

The published application covers the use of 3-Methylmethcathinone (3-MMC) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC. The application also includes claims for combinations of 3-MMC with Palmitoylethanolamide (PEA), a compound described as having anti-inflammatory and neuroprotective properties.

The patent application is part of an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX), through which PEA technology is integrated into Clearmind's therapeutic programs.

"The publication of the patent

Clearmind patent application for dyskinesia treatment published in Japan

Thu, 08 Oct 2026 07:34:26 -0400

The patent application is part of an ongoing collaboration between Clearmind and NeuroThera Labs Inc. (TSXV: NTLX), through which PEA technology is integrated into Clearmind's therapeutic programs.

"The publication of the patent

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (“3-MMC”) for preventing, treating, or reducing dyskinesia symptoms, including pharmaceutical

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Thu, 08 Oct 2026 07:32:00 -0400

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

SciSparc unit reports GPU speedup in gene combination analysis

Wed, 07 Oct 2026 08:22:40 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that CliniQuantum Ltd., a majority-owned subsidiary of NeuroThera Labs Inc. (TSXV: NTLX), reported results from a computational benchmark of its GPU-accelerated quantum-simulation platform, according to a press release.

The platform achieved approximately 16.8 times faster processing using a single NVIDIA T4 Tensor Core GPU alongside a 64-core CPU machine, compared with the same machine running only on CPU. The benchmark was conducted on an AWS g4dn.16xlarge EC2 instance using IBM Qiskit Aer GPU-based quantum simulation.

The test used a clinical gene-expression dataset from 11 patients containing 3,531 gene-expression features. The algorithm searched for correlated three-gene configurations across

SciSparc unit reports GPU speedup in gene combination analysis

Wed, 07 Oct 2026 08:22:40 -0400

The test used a clinical gene-expression dataset from 11 patients containing 3,531 gene-expression features. The algorithm searched for correlated three-gene configurations across

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum A